MCOLN1 and nasopharyngeal carcinoma: TRPML1 may be an option as a therapeutic target in NPC because its overexpression reduces cholesterol accumulation, corrects lysosomal transport defects, and also has beneficial effects on other neurodegenerative diseases, such as Alzheimer’s disease, by enhancing dynein-dependent lysosomal transport by promoting the release of lysosomal Ca2+.